Filing Details
- Accession Number:
- 0001209191-23-007032
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-03 17:09:17
- Reporting Period:
- 2023-02-01
- Accepted Time:
- 2023-02-03 17:09:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1557746 | Aclaris Therapeutics Inc. | ACRS | Pharmaceutical Preparations (2834) | 460571712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1604457 | Neal Walker | C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-01 | 25,000 | $16.75 | 1,180,763 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 1,079 | $14.57 | 1,179,684 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 600 | $15.55 | 1,179,084 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 3,121 | $16.88 | 1,175,963 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 200 | $17.54 | 1,175,763 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.28 to $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.25 to $15.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.27 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.51 to $17.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
Billionaire Hedge Funds
